Dellamonica P, Bernard E
Department of Infectious Diseases, Archet Hospital, Nice, France.
Drugs. 1993;45 Suppl 3:102-13. doi: 10.2165/00003495-199300453-00018.
The objective of surgical prophylaxis is to prevent wound infections associated with surgery. The rates of wound infections vary according to the procedure: less than 3 infections per 100 for clean procedures; up to 4 per 100 for clean-contaminated procedures; and up to 9 per 100 for contaminated procedures. Surgical antimicrobial prophylaxis has been shown in many randomised clinical trials to reduce the incidence of postoperative wound infections. Such prophylaxis is actually recommended in many clean-contaminated and some clean procedures. Because of their antimicrobial, pharmacokinetic, and antiadhesive properties, the fluoroquinolones have been recently proposed as prophylactic agents. Fluoroquinolones have proved to be useful in surgical prophylaxis and clinical trials have been performed in orthopaedic, cardiovascular, biliary, colorectal and urological surgery. According to the surgical procedure, fluoroquinolones were compared either with the standard antimicrobial regimen or with placebo. Different regimens of fluoroquinolones were also compared. Generally, fluoroquinolones have been demonstrated to be as effective as the reference prophylactic agent. In transurethral surgery, fewer postoperative wound infections were reported in the treated group than in the placebo group. In most studies, single dose prophylaxis was as effective as a multiple dose regimen. It is important to note that strict methodology was limited to a few clinical trials. In most of the studies, patients were not randomised in a double-blind fashion and small patient numbers often prevented the formation of satisfactory conclusions. Further trials are needed to define the role of the fluoroquinolones in surgical prophylaxis. It will be important to evaluate not only the efficacy but also the cost-benefit of perioperative prophylaxis with the fluoroquinolones. Clinical trials are also required in other high risk clean procedures such as neurosurgery involving shunts and ocular surgery. However, the risks related to the extensive use of fluoroquinolones in surgical prophylaxis must be considered, including the development and dissemination of resistant pathogens and the occurrence of adverse effects. In the future, surgical prophylaxis with prosthetic devices coated with fluoroquinolones should be considered.
外科预防的目的是预防与手术相关的伤口感染。伤口感染率因手术类型而异:清洁手术每100例中感染少于3例;清洁-污染手术每100例中感染可达4例;污染手术每100例中感染可达9例。多项随机临床试验表明,外科抗菌预防可降低术后伤口感染的发生率。实际上,许多清洁-污染手术和一些清洁手术都推荐进行此类预防。由于氟喹诺酮类药物具有抗菌、药代动力学和抗黏附特性,最近有人提议将其作为预防用药。氟喹诺酮类药物已被证明在外科预防中有用,并且已经在骨科、心血管、胆道、结直肠和泌尿外科手术中进行了临床试验。根据手术程序,将氟喹诺酮类药物与标准抗菌方案或安慰剂进行了比较。还比较了不同的氟喹诺酮类药物给药方案。一般来说,氟喹诺酮类药物已被证明与参考预防药物一样有效。在经尿道手术中,治疗组报告的术后伤口感染少于安慰剂组。在大多数研究中,单剂量预防与多剂量方案一样有效。需要注意的是,严格的方法学仅在少数临床试验中使用。在大多数研究中,患者并非以双盲方式随机分组,而且患者数量较少常常妨碍得出令人满意的结论。需要进一步的试验来确定氟喹诺酮类药物在外科预防中的作用。评估氟喹诺酮类药物围手术期预防的疗效以及成本效益将很重要。其他高风险清洁手术,如涉及分流器的神经外科手术和眼科手术,也需要进行临床试验。然而,必须考虑在外科预防中广泛使用氟喹诺酮类药物相关的风险,包括耐药病原体的产生和传播以及不良反应的发生。未来,应考虑使用涂有氟喹诺酮类药物的假体装置进行外科预防。